Collectively, these findings demonstrate that CAR-M orchestrates dual antitumor mechanisms: direct tumor elimination via innate immune pathways (PI3K-AKT and cGAS-STING) and indirect adaptive immune activation through chemokine-driven T cell recruitment and antigen presentation, suggesting potent combinatorial therapeutic efficacy. This evidence concerns the gene STING1 and neoplasm.